High-affinity binding of the cell cycle-regulated transcription factors E2F1 and E2F4 to benzo[a]pyrene diol epoxide-DNA adducts

Molecular Carcinogenesis

Volumn 20, Issue 2, 1997, Pages 216-223

  Johnson, David G ^a   Coleman, Angela ^a   Powell, K Leslie ^a   MacLeod, Michael C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

DNA adducts; Molecular hijacking; Polycyclic aromatic hydrocarbon; Transcription factor E2F

Indexed keywords

DIHYDROXYBENZO[A]PYRENE OXIDE; TRANSCRIPTION FACTOR E2F;

ARTICLE; BINDING AFFINITY; CELL CYCLE; DIMERIZATION; DNA ADDUCT; DNA BINDING; DNA MODIFICATION; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; ONCOGENE C MYC; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; BINDING SITES; CARRIER PROTEINS; CELL CYCLE PROTEINS; DIMERIZATION; DNA ADDUCTS; DNA PROBES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; E2F4 TRANSCRIPTION FACTOR; ELECTROPHORESIS; FUNGAL PROTEINS; HELA CELLS; HUMANS; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS;

EID: 0030690034     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199710)20:2<216::AID-MC8>3.0.CO;2-K     Document Type: Article

References (45)

1. Dalla-Favera R, Bregni M, Erickson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824-7827, 1982.
2. Davis M, Malcolm S, Rabbitts TH. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature 308:286-288, 1984.
3. Hollis GF, Mitchell KF, Battey J, et al. A variant translocation places the lambda immunoglobulin genes 3′ to the c-myc oncogene in Burkitt's lymphoma. Nature 307:752-755, 1984.
4. Eick D, Bornkamm GW. Expression of normal and translocated c-myc alleles in Burkitt's lymphoma cells: Evidence for different regulation. EMBO J 8:1965-1972, 1989.
5. Grignani F, Lombardi L, lnghirami G, Sternas L, Cechova K, Dalla-Favera R. Negative autoregulation of c-myc gene expression is inactivated in transformed cells. EMBO J 9:3913-3922, 1990.
6. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238:1386-1392, 1987.
7. Sassone-Corsi P, Sisson JC, Verma IM. Transcriptional autoregulation of the proto-oncogene fos. Nature 334:314-319, 1988.
8. Ku DH, Wen SC, Engelhard A, et al. c-myb transactivates cdc2 expression via myb binding sites in the 5′-flanking region of the human cdc2 gene. J Biol Chem 268:2255-2259, 1993.
9. Aplan PD, Nakahara K, Orkin SH, Kirsch IR. The SCL gene product: A positive regulator of erythroid differentiation. EMBO J 11:4073-4081, 1992.
10. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/ zinc finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 93:6947-6952, 1996.
11. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 255:1708-1711, 1991.
12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994.
13. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol 15:4623-4630, 1995.
14. Brown AD, Lope-Terrada D, Denny C, Lee KA. Promoters containing ATF-binding sites are de-regulated in cells that express the EWS/ATF1 oncogene. Oncogene 10:1749-1756, 1995.
15. Werner H, Shen-Orr Z, Rauscher FJ III, Morris JF, Roberts CT, Jr., LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-3522, 1995.
16. Slansky JE, Farnham PJ. Introduction to the E2F family: Protein structure and gene regulation. Curr Top Microbiol Immunol 208:1-30, 1996.
17. Treiber DK, Zhai X, Jantzen H-M, Essigman JM. Cisplatin-DNA adducts are molecular decoys for the ribosomal transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci USA 91:5672-5676, 1994.
18. MacLeod MC, Powell KL, Tran N. Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. Carcinogenesis 16:975-983, 1995.
19. Sun D, Hurley LH. TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin. Chemistry Biology 2:457-469, 1995.
20. Dorn A, Affolter M, Muller M, Gehring WJ, Leupin W. Distamycin-induced inhibition of homeodomain-DNA complexes. EMBO J 11:279-286, 1992.
21. Butler AP, Johnson DG, Kumar AP, Narayan S, Wilson SH, MacLeod MC. Disruption of transcription in vitro and gene expression in vivo by DNA adducts derived from a benzo[a]pyrene diol epoxide located in heterologous sequences. Carcinogenesis 18:239-244, 1997.
22. MacLeod MC, Powell KL, Kuzmin VA, Kolbanovskiy A, Geacintov NE. Interference of benzo[a]pyrene diol epoxide-deoxyguanosine adducts in a GC box with binding of the transcription factor Sp1. Mol Carcinog 16:44-52, 1996.
23. Sun D, Hurley LH. Cooperative bending of the 21-base pair repeats of the SV40 viral early promoter by human Sp1. Biochemistry 33:9578-9587, 1994.
24. Horikoshi M, Bertuccioli C, Takada R, Wang J, Yamamoto T, Roeder RG. Transcription factor TFIID induces DNA bending upon binding to the TATA element. Proc Natl Acad Sci USA 89:1060-1064, 1992.
25. Kerppola TK, Curran T. DNA bending by Fos and Jun: The flexible hinge model. Science 254:1210-1214, 1991.
26. Wechsler DS, Dang CV. Opposite orientations of DNA bending by c-Myc and Max. Proc Natl Acad Sci USA 89:7635-7639, 1992.
27. Saikumar P, Gabriel JL, Reddy EP. The Myb oncogene product induces DNA-bending. Oncogene 9:1279-1287, 1994.
28. Huber HE, Goodhart PJ, Huang PS. Retinoblastoma protein reverses DNA bending by transcription factor E2F. J Biol Chem 269:6999-7005, 1994.
29. Cress WD, Nevins JR. A role for a bent DNA structure in E2F-mediated transcription activation. Mol Cell Biol 16:2119-2127, 1996.
30. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/ S-regulatory genes. Mol Cell Biol 15:4215-4224, 1995.
31. Lam EWF, Watson RJ. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J 12:2705-2713, 1993.
32. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8:1514-1525, 1994.
33. Marmorstein R, Carey M, Ptashne M, Harrison SC. DNA recognition by GAL4: Structure of a protein-DNA complex. Nature 356:408-414, 1992.
34. Kim J, Zwieb C, Wu C, Adhya S. Bending of DNA by gene-regulatory proteins: Construction and use of a DNA bending vector Gene 85:15-23, 1989.
35. Lin Y-S, Carey M, Ptashne M, Green MR. How different eukaryotic transcriptional activators can cooperate promiscuously. Nature 345:359-361, 1990.
36. Yee AS, Raychaudhuri P, Jakoi L, Nevins JR. The adenovirus-inducible factor E2F stimulates transcription after specific DNA binding. Mol Cell Biol 9:578-585, 1989.
37. Helin K, Lees JA, Vidal M, Dyson N, Harlow E. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70:337-350, 1992.
38. Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L, Voorhoeve PM, Bernards R. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 8:2680-2690, 1994.
39. Helin K, Wu CL, Fattaey AR, et al. Heterodimerization of the transcription factors E2F1 and DP1 leads to cooperative transactivation. Genes Dev 7:1850-1861, 1993.
40. Xu R, Mao B, Xu J, et al. Stereochemistry-dependent bending in oligonucleotide duplexes induced by site-specific covalent benzo[a]pyrene diol epoxide-guanine lesions. Nucleic Acids Res 23:2314-2319, 1995.
41. Liu T, Xu J, Tsao H, et al. Base sequence-dependent bends in site-specific benzo[a]pyrene diol epoxide-modified oligonucleotide duplexes. Chem Res Toxicol 9:255-261, 1996.
42. Erie DA, Yang G, Schultz HC, Bustamente C. DNA bending by Cro protein in specific and nonspecific complexes: Implications for protein site recognition and specificity. Science 266:1562-1566, 1994.
43. Persson AE, Ponten I, Cotgreave I, Jernstrom B. Inhibitory effects on the DNA binding of AP-1 transcription factor to an AP-1 binding site modified by benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxide diastereomers. Carcinogenesis 17:1963-1969, 1996.
44. Tommasi S, Swiderski PM, Tu Y, Kaplan BE, Pfeifer GP. Inhibition of transcription factor binding by ultraviolet-induced pyrimidine dimers. Biochemistry 35:15693-15703, 1996.
45. MacLeod MC. A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. Mol Carcinog 15:241-250, 1996.